MannKind Dirección
Dirección controles de criterios 2/4
MannKind's El consejero delegado es Michael Castagna , nombrado en May 2017, tiene un mandato de 6.58 años. la remuneración anual total es $3.91M , compuesta por 16% salario y 84% primas, incluidas acciones y opciones de la empresa. posee directamente 0.87% de las acciones de la empresa, por valor de $8.32M . La antigüedad media del equipo directivo y del consejo de administración es de 6.4 años y 4.5 años respectivamente.
Información clave
Michael Castagna
Chief Executive Officer (CEO)
US$7.1m
Compensación total
| Porcentaje del salario del CEO | 9.9% |
| Permanencia del CEO | 6.9yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 6.8yrs |
| Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17MannKind (MNKD) earns $12.5M milestone under licensing deal for treprostinil
Nov 20MannKind: Global Product Sales, Late-Stage Clinical Pipeline Candidate, And Strong Leadership, 34% Upside
Nov 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$61m |
| Mar 31 2019 | n/a | n/a | -US$71m |
| Dec 31 2018 | US$2m | US$500k | -US$87m |
| Sep 30 2018 | n/a | n/a | -US$110m |
| Jun 30 2018 | n/a | n/a | -US$119m |
| Mar 31 2018 | n/a | n/a | -US$131m |
| Dec 31 2017 | US$1m | US$459k | -US$117m |
Compensación vs. Mercado: Michael($USD7.07M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.30M).
Compensación vs. Ingresos: La compensación de Michael ha aumentado mientras la empresa no es rentable.
CEO
Michael Castagna (46 yo)
6.9yrs
Permanencia
US$7,068,114
Compensación
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.9yrs | US$7.07m | 0.34% $ 3.7m | |
| Chief Financial Officer | 6.8yrs | US$2.34m | 0.16% $ 1.8m | |
| Executive VP & COO | 1.1yrs | US$2.74m | 0.0048% $ 53.5k | |
| Executive VP | 22.3yrs | US$2.34m | 0.14% $ 1.5m | |
| Executive VP and Chief People & Workplace Officer | 7.3yrs | US$2.22m | 0.22% $ 2.5m | |
| Executive Vice President of Technical Operations | 1.5yrs | US$1.12m | 0.014% $ 153.2k | |
| VP of Investor Relations & Treasury | 6.8yrs | US$519.59k | sin datos | |
| Senior Vice President of Worldwide Regulatory Affairs | 18.5yrs | sin datos | sin datos | |
| Chief Commercial Officer | 6.8yrs | US$921.51k | sin datos | |
| Executive VP of Research & Development and Chief Medical Officer | less than a year | sin datos | 0.058% $ 644.3k |
6.8yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: MNKDEl equipo directivo de la empresa es veterano y experimentado (6.4 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.9yrs | US$7.07m | 0.34% $ 3.7m | |
| Independent Director | 20.5yrs | US$241.73k | 0.044% $ 483.2k | |
| Independent Director | 19.8yrs | US$240.64k | 0.098% $ 1.1m | |
| Independent Director | 5.4yrs | US$197.88k | 0.010% $ 112.9k | |
| Independent Director | 20.3yrs | US$200.38k | 0.0055% $ 61.0k | |
| Independent Director | 4.3yrs | US$200.38k | 0.065% $ 718.7k | |
| Independent Chairman | 8.9yrs | US$255.64k | 0.0090% $ 99.8k | |
| Independent Director | 3.3yrs | US$221.73k | 0.040% $ 436.7k | |
| Member of Scientific Advisory Board | 2.7yrs | sin datos | sin datos | |
| Independent Director | 4.1yrs | US$192.88k | 0.041% $ 451.6k | |
| Member of Scientific Advisory Board | 2.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.7yrs | sin datos | sin datos |
4.8yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: La junta directiva de MNKD se considera experimentada (4.5 años de antigüedad promedio).